Paul Hartmann AG vs. Attends Healthcare: Federal Circuit Vacates & Remands Incontinence Patent Ruling
What would you like to do next?
Choose your path based on your current needs:
Learn from this case
Understand the legal analysis, timeline, and key takeaways
RecommendedCheck my product’s risk
Run FTO analysis for your own technology or product
Explore patent landscape
View related patents and competitive intelligence
📋 Case Summary
| Case Name | Paul Hartmann AG v. Attends Healthcare Products, Inc. |
| Case Number | 22-1726 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB/District Court |
| Duration | Apr 2022 – Mar 2024 1 year 11 months |
| Outcome | Vacated & Remanded |
| Patents at Issue | |
| Accused Products | Attends Healthcare’s Absorbent Incontinence Articles |
Case Overview
The Parties
⚖️ Plaintiff
German multinational healthcare company with a substantial portfolio in wound care, incontinence management, and hygiene products.
🛡️ Defendant
U.S.-based manufacturer specializing in adult incontinence and continence care products, competing in the market segment covered by Hartmann’s IP.
The Patent at Issue
This case involved a single, commercially critical patent covering an improved closure system for absorbent incontinence products. This technology directly impacts product performance, user comfort, and manufacturing cost differentiation.
- • US8771249B2 — Improved closure system for absorbent incontinence articles
Innovating in medical devices or personal care?
Check if your product design might infringe this or related patents before launch.
Litigation Timeline & Procedural History
The case was filed directly at the **Federal Circuit** level on April 26, 2022, indicating it arose from an appeal of a prior administrative or district court proceeding — likely a **Patent Trial and Appeal Board (PTAB) inter partes review (IPR)** or a district court invalidity determination, consistent with the “Invalidity/Cancellation Action” verdict cause classification.
| Appeal Filed | April 26, 2022 |
| Court | U.S. Court of Appeals for the Federal Circuit |
| Case Closed | March 4, 2024 |
| Total Duration | 678 days (~22 months) |
A 678-day appellate timeline is within the normal range for Federal Circuit patent appeals, which typically require comprehensive briefing, potential oral argument, and panel deliberation. The case’s classification under the **District of Columbia** circuit region reflects the Federal Circuit’s Washington, D.C. jurisdictional seat, consistent with all patent appeals consolidated at that court.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued an order **vacating and remanding** the prior ruling. No damages award or injunctive relief is reflected in the case record. The remand returns the matter to the originating tribunal — whether PTAB or district court — for further proceedings consistent with the appellate court’s guidance.
A vacatur-and-remand outcome does not represent a win or loss on the merits for either party in a conventional sense. Rather, it indicates the Federal Circuit identified a legal or procedural error in the lower tribunal’s analysis sufficient to require correction before a final patentability determination can stand.
Verdict Cause Analysis
The verdict cause is classified as **Patentability — Invalidity/Cancellation Action**, which strongly suggests this appeal arose from an administrative invalidity proceeding, most likely an **inter partes review (IPR)** at the PTAB challenging US8771249B2.
The Federal Circuit’s decision to vacate rather than affirm or reverse outright suggests one or more of the following occurred: erroneous claim construction, incomplete obviousness analysis, inadequate consideration of secondary considerations, or procedural deficiency.
Legal Significance
This case reinforces several important Federal Circuit principles:
- PTAB decisions are not insulated from appellate scrutiny.
- Claim construction remains a high-stakes gateway issue.
- Medical device and personal care patents receive no reduced scrutiny.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device and personal care product design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in the absorbent article technology space
- Analyze active companies in incontinence product IP
- Understand patent claim trends in medical devices
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Absorbent Article Closure Systems
Active Patent
US8771249B2 (Pending Remand)
Remand Outcome
Extends Uncertainty for FTO
✅ Key Takeaways
Federal Circuit vacated the PTAB/lower ruling — patentability determination remains unresolved; monitor remand proceedings in Case No. 22-1726.
Search related case law →Invalidity/cancellation actions under IPR remain subject to Federal Circuit correction for legal error, including claim construction and obviousness analysis deficiencies.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. US8771249B2 (Application No. US13/798,242), covering an absorbent incontinence article with an improved closure system.
The Federal Circuit found a legal error in the lower tribunal’s patentability analysis and returned the case for corrected proceedings — neither affirming the invalidity finding nor declaring the patent definitively valid.
It signals that invalidity challenges to incontinence product patents face meaningful appellate risk, and that patent holders with strong prosecution histories and commercial evidence can successfully challenge PTAB cancellation rulings on appeal.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center — US8771249B2
- Federal Circuit Case Search — PACER
- USPTO — PTAB Trial Statistics
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.